We’re wrapping up AD/PD 2025 inspired and ready to take action!

A few final highlights: two standout presentations revealed how both molecular and epigenetic biomarkers are reshaping the future of Alzheimer’s diagnostics. In “Measurement of CSF MTBR-tau243 in Clinical Trials of Alzheimer’s Disease and Progressive Supranuclear Palsy,” researchers examined gosuranemab, an anti-tau antibody targeting the N-terminus of tau. While gosuranemab consistently reduced CSF MTBR-tau243 levels across multiple trials, it failed to produce changes in tau PET imaging or clinical endpoints. This disconnect highlights the complexity of tau-targeting therapies and the need for more refined tools to interpret biological impact. Despite this, MTBR-tau243 remains a promising candidate as a treatment response biomarker, particularly when measured using highly sensitive platforms like Quanterix’s Simoa®. The ability to detect subtle changes in tau species in CSF and plasma is critical to assessing early drug effects and understanding disease mechanisms. Fluid biomarkers are proving to be more dynamic and immediate readouts of biological change than imaging alone. 

In a second session, “Biological Age and Age Acceleration Strongly Predict Alzheimer’s Disease Plasma Biomarker Levels,” researchers explored how epigenetic clocks can provide deeper insight into disease risk. Using DNA methylation data from 739 Caribbean Hispanics with AD or a family history of it, they calculated biological age using Hannum, Horvath, and Levine clocks. They found that both biological age and age acceleration strongly predicted levels of plasma biomarkers like P-tau217, GFAP, NFL, and Aβ40. Notably, these associations were especially strong in women, suggesting sex-specific aging trajectories. 

These findings suggest that biological age may offer more predictive value than chronological age when it comes to Alzheimer’s progression. By combining epigenetic signatures with fluid biomarker data, researchers can improve risk stratification and refine diagnostic precision. As the field continues to evolve, Quanterix is enabling researchers to detect and quantify these biomarkers with unprecedented sensitivity, helping turn molecular insights into actionable clinical strategies. 

We also closed out our in-booth speaking sessions with three more great talks! 

• Tianyi Wang, Peking Union Medical College Hospital, Blood Biomarkers for Identifying Alzheimer’s Disease Pathology in Dementia Patients. 

• Michael Khalil, Medical University of Graz, Current status of sNfL and implementation in clinical practice 

• Soumilee Chaudhuri, Indiana Alzheimer’s Disease Research Center, Cardiovascular risk and its association with plasma biomarkers along the Alzheimer’s Disease trajectory 

Quanterix’s presence at AD/PD 2025 reflected not only the strength of our science, but the power of collaboration and community in driving the field forward. From packed in-booth presentations to meaningful conversations with researchers and clinicians from around the world, it was clear that the appetite for high-sensitivity, accessible biomarker tools has never been greater. As the neuroscience landscape continues to evolve—from preclinical detection to personalized care—Quanterix remains committed to empowering discovery with the tools that make next-generation diagnostics possible. Thank you to everyone who joined us in Vienna. We’re energized by what’s ahead. 

Read the key takeaways from Day 4 here.